Company intelligence / Profile preview

Cellavita Pesquisas Científicas Ltda

Ownership: Private
Development stage: Phase 3

Overview

Cellavita has advanced NestaCell®, a mesenchymal stem cell therapy derived from human dental pulp, into Phase 3 clinical trials for moderate Huntington’s disease. Earlier phase I/II studies showed significant improvement in motor scores and functional capacity versus placebo, with good safety and tolerability. NestaCell® also completed a Phase 2 trial for severe COVID‑19 pneumonia.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Mesenchymal stem cells (MSC)Human Dental Pulp Stem Cells (hDPSCs)
Industry: Biotech

Drug pipeline

1 asset

Cellavita HD

Unknown

Partnerships

Butantan Institute (Brazil) – partnership to develop hDPSC-based therapies for neurodegenerative diseases including HDAzidus Brasil – clinical trial sponsor/collaborator for HD program

Beyond the preview

Go deeper on Cellavita Pesquisas Científicas Ltda.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellavita Pesquisas Científicas Ltda.

Explore the full profile